
    
      A randomized phase III study is going to started in Japan to compare TS-1 plus cisplatin as a
      neoadjuvant chemotherapy with surgery alone in patient with type 4 and large type 3 gastric
      cancer.A total of 300 patients will be accrued for this study from 35 institutions within
      five years. The primary endpoint is overall survival. The secondary endpoints are progression
      free survival (PFS), response rate, proportion of protocol achievement, proportion of
      curative resection, and adverse events.
    
  